文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛消化、代谢与肾脏急症

抗白介素药物对COVID-19合并细胞因子释放综合征患者的效果(COV-AID):一项析因随机对照试验

Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial.
PubMed 文献 · Lancet Respir Med · 2021-10-29
一句话结论在COVID-19、缺氧性呼吸衰竭、低SOFA评分且基线死亡风险低的患者中,靶向IL-1或IL-6的药物未缩短临床改善时间。

COV-AID是一项在比利时16家医院开展的前瞻性、多中心、开放标签、随机对照试验,采用2×2析因设计,纳入342例COVID-19、缺氧和细胞因子释放综合征征象的住院患者。患者随机接受IL-1阻断(阿那白滞素皮下100 mg每日一次,用28天或至出院)或不阻断,以及IL-6阻断(托珠单抗8 mg/kg单次静脉或司妥昔单抗11 mg/kg单次静脉)或不阻断。主要终点临床改善时间在IL-1阻断组为12天(95% CI 10-16)vs 无IL-1阻断组12天(10-15)(HR 0.94,95% CI 0.73-1.21);IL-6阻断组为11天(95% CI 10-16)vs 无IL-6阻断组12天(11-16)(HR 1.00,95% CI 0.78-1.29),均无显著差异。55例患者死亡,治疗组间死亡率无差异,严重不良事件和严重感染发生率相似。

要点

  • 在COVID-19、缺氧性呼吸衰竭、低SOFA评分(中位3分)且基线死亡风险低的患者中,IL-1阻断(阿那白滞素)未缩短临床改善时间:12天 vs 12天,HR 0.94(95% CI 0.73-1.21)。
  • IL-6阻断(托珠单抗或司妥昔单抗)同样未缩短临床改善时间:11天 vs 12天,HR 1.00(95% CI 0.78-1.29)。
  • 研究期间55例患者死亡,但未发现治疗组间死亡率存在差异。
  • 严重不良事件和严重感染的发生率在各研究组间相似。
  • 作者结论:靶向IL-1或IL-6的药物未缩短该样本患者的临床改善时间。

适用人群与场景

  • 住院的COVID-19患者,症状持续6至16天,存在缺氧和细胞因子释放综合征征象。
  • 纳入标准:PaO2:FiO2在室内空气下<350 mm Hg或 supplemental oxygen下<280 mm Hg;且血清细胞因子释放综合征征象满足以下任一:单次铁蛋白>2000 μg/L且立即需要高流量氧疗或有创机械通气;或铁蛋白>1000 μg/L且过去24小时进行性升高;或淋巴细胞减少<800/mL且满足以下两项:铁蛋白进行性升高>700 μg/L、乳酸脱氢酶进行性升高>300 IU/L、C反应蛋白进行性升高>70 mg/L、D-二聚体进行性升高>1000 ng/mL。

诊断标准与关键阈值

  • 临床改善定义:随机化后至6分类序数量表评分增加至少2分或活着出院的时间。
  • 细胞因子释放综合征的血清学标准如上(铁蛋白、淋巴细胞、LDH、CRP、D-二聚体界值)。

处置流程与药物剂量

  • IL-1阻断:阿那白滞素100 mg皮下注射,每日一次,持续28天或至出院。
  • IL-6阻断:托珠单抗8 mg/kg单次静脉注射,或司妥昔单抗11 mg/kg单次静脉注射。
  • 对照:不进行IL-1阻断或不进行IL-6阻断。

研究设计与关键结果

  • 研究类型:前瞻性、多中心、开放标签、随机对照试验,2×2析因设计,在比利时16家医院开展,纳入342例患者。
  • 随机分配:IL-1阻断组112例 vs 无IL-1阻断组230例;同时随机分配至IL-6阻断组227例(托珠单抗114例,司妥昔单抗113例)vs 无IL-6阻断组115例。
  • 人群特征:男性265例(77%),中位年龄65岁(IQR 54-73),随机化时中位SOFA评分3分(2-4)。
  • 主要终点:IL-1阻断组估计中位临床改善时间12天(95% CI 10-16)vs 无IL-1阻断组12天(10-15),HR 0.94(95% CI 0.73-1.21);IL-6阻断组11天(95% CI 10-16)vs 无IL-6阻断组12天(11-16),HR 1.00(95% CI 0.78-1.29)。
  • 死亡:研究期间55例患者死亡,未发现治疗组间死亡率差异。
  • 安全性:严重不良事件和严重感染发生率在各研究组间相似。

证据类型、等级与局限

  • 证据类型:前瞻性、多中心、开放标签、随机对照试验(2×2析因设计)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者结论:靶向IL-1或IL-6的药物未缩短该样本COVID-19、缺氧性呼吸衰竭、低SOFA评分和低基线死亡风险患者的临床改善时间。

指南或共识出处

  • COV-AID试验注册于ClinicalTrials.gov(NCT04330638)和EudraCT(2020-001500-41)。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Infections with SARS-CoV-2 continue to cause significant morbidity and mortality. Interleukin (IL)-1 and IL-6 blockade have been proposed as therapeutic strategies in COVID-19, but study outcomes have been conflicting. We sought to study whether blockade of the IL-6 or IL-1 pathway shortened the time to clinical improvement in patients with COVID-19, hypoxic respiratory failure, and signs of systemic cytokine release syndrome.

METHODS: We did a prospective, multicentre, open-label, randomised, controlled trial, in hospitalised patients with COVID-19, hypoxia, and signs of a cytokine release syndrome across 16 hospitals in Belgium. Eligible patients had a proven diagnosis of COVID-19 with symptoms between 6 and 16 days, a ratio of the partial pressure of oxygen to the fraction of inspired oxygen (PaO2:FiO2) of less than 350 mm Hg on room air or less than 280 mm Hg on supplemental oxygen, and signs of a cytokine release syndrome in their serum (either a single ferritin measurement of more than 2000 μg/L and immediately requiring high flow oxygen or mechanical ventilation, or a ferritin concentration of more than 1000 μg/L, which had been increasing over the previous 24 h, or lymphopenia below 800/mL with two of the following criteria: an increasing ferritin concentration of more than 700 μg/L, an increasing lactate dehydrogenase concentration of more than 300 international units per L, an increasing C-reactive protein concentration of more than 70 mg/L, or an increasing D-dimers concentration of more than 1000 ng/mL). The COV-AID trial has a 2 × 2 factorial design to evaluate IL-1 blockade versus no IL-1 blockade and IL-6 blockade versus no IL-6 blockade. Patients were randomly assigned by means of permuted block randomisation with varying block size and stratification by centre. In a first randomisation, patients were assigned to receive subcutaneous anakinra once daily (100 mg) for 28 days or until discharge, or to receive no IL-1 blockade (1:2). In a second randomisation step, patients were allocated to receive a single dose of siltuximab (11 mg/kg) intravenously, or a single dose of tocilizumab (8 mg/kg) intravenously, or to receive no IL-6 blockade (1:1:1). The primary outcome was the time to clinical improvement, defined as time from randomisation to an increase of at least two points on a 6-category ordinal scale or to discharge from hospital alive. The primary and supportive efficacy endpoints were assessed in the intention-to-treat population. Safety was assessed in the safety population. This study is registered online with ClinicalTrials.gov (NCT04330638) and EudraCT (2020-001500-41) and is complete.

FINDINGS: Between April 4, and Dec 6, 2020, 342 patients were randomly assigned to IL-1 blockade (n=112) or no IL-1 blockade (n=230) and simultaneously randomly assigned to IL-6 blockade (n=227; 114 for tocilizumab and 113 for siltuximab) or no IL-6 blockade (n=115). Most patients were male (265 [77%] of 342), median age was 65 years (IQR 54-73), and median Systematic Organ Failure Assessment (SOFA) score at randomisation was 3 (2-4). All 342 patients were included in the primary intention-to-treat analysis. The estimated median time to clinical improvement was 12 days (95% CI 10-16) in the IL-1 blockade group versus 12 days (10-15) in the no IL-1 blockade group (hazard ratio [HR] 0·94 [95% CI 0·73-1·21]). For the IL-6 blockade group, the estimated median time to clinical improvement was 11 days (95% CI 10-16) versus 12 days (11-16) in the no IL-6 blockade group (HR 1·00 [0·78-1·29]). 55 patients died during the study, but no evidence for differences in mortality between treatment groups was found. The incidence of serious adverse events and serious infections was similar across study groups.

INTERPRETATION: Drugs targeting IL-1 or IL-6 did not shorten the time to clinical improvement in this sample of patients with COVID-19, hypoxic respiratory failure, low SOFA score, and low baseline mortality risk.

FUNDING: Belgian Health Care Knowledge Center and VIB Grand Challenges program.

来源:Lancet Respir Med,查看原文。版权归原作者所有。

参考来源

  1. Declercq J, Van Damme KFA, De Leeuw E, et al. Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial. Lancet Respir Med. 2021. PMID: 34756178. doi:10.1016/S2213-2600(21)00377-5

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。